William A. Wegener

7.4k total citations · 1 hit paper
125 papers, 4.7k citations indexed

About

William A. Wegener is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, William A. Wegener has authored 125 papers receiving a total of 4.7k indexed citations (citations by other indexed papers that have themselves been cited), including 65 papers in Radiology, Nuclear Medicine and Imaging, 46 papers in Oncology and 45 papers in Pathology and Forensic Medicine. Recurrent topics in William A. Wegener's work include Monoclonal and Polyclonal Antibodies Research (46 papers), Lymphoma Diagnosis and Treatment (41 papers) and Radiopharmaceutical Chemistry and Applications (35 papers). William A. Wegener is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (46 papers), Lymphoma Diagnosis and Treatment (41 papers) and Radiopharmaceutical Chemistry and Applications (35 papers). William A. Wegener collaborates with scholars based in United States, France and Germany. William A. Wegener's co-authors include David M. Goldenberg, Robert M. Sharkey, Linda T. Vahdat, Heather Horne, Aditya Bardia, Gerd R Burmester, Nick Teoh, John P. Leonard, Morton Coleman and Serengulam V. Govindan and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Journal of Chemical Physics.

In The Last Decade

William A. Wegener

124 papers receiving 4.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer

2019 599 citations Aditya Bardia, Linda T. Vahdat et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
William A. Wegener United States	36	2.2k	1.9k	1.1k	931	767	125	4.7k
Yvette L. Kasamon United States	34	2.1k 1.0×	2.3k 1.2×	980 0.9×	1.3k 1.4×	620 0.8×	99	5.9k
B.K. Dallaire United States	16	2.0k 0.9×	1.5k 0.8×	2.7k 2.4×	1.4k 1.5×	817 1.1×	19	5.0k
F. Jänicke Germany	54	5.5k 2.5×	1.8k 0.9×	715 0.6×	605 0.6×	3.1k 4.0×	183	11.3k
Malik E. Juweid United States	31	2.7k 1.2×	3.5k 1.9×	4.7k 4.2×	622 0.7×	737 1.0×	126	8.1k
Gregory A. Wiseman United States	43	2.6k 1.2×	3.6k 2.0×	4.1k 3.6×	509 0.5×	542 0.7×	113	8.5k
Joseph G. Rajendran United States	29	902 0.4×	2.0k 1.1×	825 0.7×	249 0.3×	398 0.5×	74	3.8k
Christine A. White United States	22	2.8k 1.3×	2.9k 1.6×	4.6k 4.2×	1.7k 1.8×	651 0.8×	34	7.1k
Guillaume Cartron France	44	3.3k 1.5×	2.5k 1.4×	3.6k 3.2×	2.7k 2.9×	2.0k 2.6×	268	8.4k
Stewart Kroll United States	29	1.3k 0.6×	1.8k 0.9×	1.5k 1.3×	281 0.3×	596 0.8×	71	4.0k
Phuoc T. Tran United States	47	2.3k 1.0×	1.0k 0.6×	548 0.5×	785 0.8×	2.5k 3.2×	254	6.4k

Countries citing papers authored by William A. Wegener

Since Specialization

Citations

This map shows the geographic impact of William A. Wegener's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William A. Wegener with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William A. Wegener more than expected).

Fields of papers citing papers by William A. Wegener

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William A. Wegener. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William A. Wegener. The network helps show where William A. Wegener may publish in the future.

Co-authorship network of co-authors of William A. Wegener

This figure shows the co-authorship network connecting the top 25 collaborators of William A. Wegener. A scholar is included among the top collaborators of William A. Wegener based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William A. Wegener. William A. Wegener is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kalinsky, Kevin, Jennifer R. Diamond, Linda T. Vahdat, et al.. (2020). Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial. Annals of Oncology. 31(12). 1709–1718. 111 indexed citations

Heist, Rebecca S., Michael J. Guarino, Gregory A. Masters, et al.. (2017). Therapy of Advanced Non–Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan. Journal of Clinical Oncology. 35(24). 2790–2797. 139 indexed citations

Faltas, Bishoy M., Elaine T. Lam, Philip J. Saylor, et al.. (2017). Sacituzumab govitecan (IMMU-132) for patients with pretreated metastatic urothelial uancer (UC): interim results. Annals of Oncology. 28. v301–v302. 15 indexed citations

Liebman, Howard A., Mansoor N. Saleh, James B. Bussel, et al.. (2016). Comparison of two dosing schedules for subcutaneous injections of low-dose anti-CD20 veltuzumab in relapsed immune thrombocytopenia. Haematologica. 101(11). 1327–1332. 8 indexed citations

Starodub, Alexander, Allyson J. Ocean, Manish A. Shah, et al.. (2015). First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors. Clinical Cancer Research. 21(17). 3870–3878. 252 indexed citations

Wallace, Daniel J., Caroline Gordon, Vibeke Strand, et al.. (2013). Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up. Lara D. Veeken. 52(7). 1313–1322. 97 indexed citations

Ocean, Allyson J., Kenneth Pennington, Michael J. Guarino, et al.. (2012). Fractionated radioimmunotherapy with ⁹⁰ Y‐clivatuzumab tetraxetan and low‐dose gemcitabine is active in advanced pancreatic cancer. Cancer. 118(22). 5497–5506. 64 indexed citations

Elstrom, Rebecca, Steven L. Allen, K. R., et al.. (2010). Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin's lymphoma. Haematologica. 96(4). 567–573. 40 indexed citations

Goldenberg, David M., Franck Morschhauser, & William A. Wegener. (2010). Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects. Leukemia & lymphoma. 51(5). 747–755. 44 indexed citations

10.

Ferrer, Ludovic, Françoise Kraeber‐Bodéré, Caroline Bodet‐Milin, et al.. (2010). Three methods assessing red marrow dosimetry in lymphoma patients treated with radioimmunotherapy. Cancer. 116(S4). 1093–1100. 42 indexed citations

11.

Wallace, Daniel J., Frédéric Houssiau, Kathryn Hobbs, et al.. (2008). Epratuzumab (anti-CD22 mAb targeting b-cells) provides clinically meaningful reductions in corticosteroid (CS) use with a favorable safety profile in patients with Moderate/Severe flaring SLE: Results from Randomized controlled trials (RCTs). Arthritis & Rheumatism. 58(9). 22 indexed citations

12.

Steinfeld, Serge, Laure Tant, Gerd R Burmester, et al.. (2006). Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study. Arthritis Research & Therapy. 8(4). R129–R129. 188 indexed citations

13.

Qu, Zhengxing, Gary L. Griffiths, William A. Wegener, et al.. (2005). Development of humanized antibodies as cancer therapeutics. Methods. 36(1). 84–95. 40 indexed citations

14.

Goldenberg, David M., Hani Abdel-Nabi, Aldo N. Serafini, et al.. (2000). Carcinoembryonic antigen immunoscintigraphy complements mammography in the diagnosis of breast carcinoma. Cancer. 89(1). 104–115. 12 indexed citations

15.

Dm, Goldenberg & William A. Wegener. (1997). Studies of breast cancer imaging with radiolabeled antibodies to carcinoembryonic antigen. Immunomedics Breast Cancer Study Group.. PubMed. 24(2). 55–9. 3 indexed citations

16.

Wegener, William A. & Abass Alavi. (1991). Positron emission tomography in the investigation of neuropsychiatrie disorders: Update and comparison with magnetic resonance imaging and computerized tomography. International Journal of Radiation Applications and Instrumentation Part B Nuclear Medicine and Biology. 18(6). 569–582. 2 indexed citations

17.

Wegener, William A., et al.. (1991). Infectious imaging with indium-111-labeled nonspecific polyclonal human immunoglobulin.. PubMed. 32(11). 2079–85. 11 indexed citations

18.

Wegener, William A., et al.. (1990). Meningioma Extending Through the Skull. Clinical Nuclear Medicine. 15(6). 441–442. 4 indexed citations

19.

VELCHIK, MICHAEL G. & William A. Wegener. (1989). Osteogenic Sarcoma with Pulmonary Metastasis Visualized by Bone Imaging. Clinical Nuclear Medicine. 14(9). 662–665. 6 indexed citations

20.

Wegener, William A.. (1981). Diffusion coefficients for rigid macromolecules with irregular shapes that allow rotational‐translational coupling. Biopolymers. 20(2). 303–326. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact